Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the strongest weight loss data yet in Phase 3 trial in a pure obesity population.
May 21, 2026 06:45 AM EDTUpdated 07:02 AM
Lilly’s triple agonist still leads among late-stage obesity assets
Elizabeth Cairns
Senior biopharma journalist
Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They …
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)
Eli Lilly retatrutide Phase 3 obesity trial results 2026
Eli Lilly’s obesity drug shows up to 30% weight loss in trial
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
Super Ozempic? New weight-loss drug sees even better results in recent study
Eli Lilly diz que novo medicamento ajuda pacientes com obesidade a perder 28% do peso corporal
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body…
